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Abstract
Background: The prevalence of depression in patients with acute coronary syndrome, i.e.
myocardial infarction and unstable angina, is higher than in the general population. The prevalence
of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes
and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes
undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of
DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to
prevent depression in patients with acute coronary syndrome.
Methods: Two hundred forty non-depressed patients with acute coronary syndrome are
randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac
assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis
of depression and Hamilton Depression Scale are the primary outcome measures.
Discussion: This is the first study of prevention of depression in patients after acute coronary
syndrome with a selective serotonin reuptake inhibitor.
Trial Registration: http://www.ClinicalTrials.gov. Identifier: NCT00140257
Background
The prevalence of depression in patients recovering from
acute coronary syndrome (ACS) defined as acute myocar-
dial infarction (AMI) and unstable angina pectoris (UAP)
has been reported to be 10–40% [1-5]. Depression after
ACS is associated with increased mortality and morbidity
[6]. Furthermore, cardiac patients with depression have an
increased number of visits to general practitioners and are
less likely to return to work [5]. Among patients who sur-
vive the first post-AMI year, depression is also associated
with increased health care costs linked to both hospital
readmissions and out-patient contacts [7]. The negative
impact of depression has been observed not only in
patients with an established diagnosis of depression, but
also in patients who reported symptoms of depression
during hospitalization [8].
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Trials 2009, 10:20 http://www.trialsjournal.com/content/10/1/20Anxiety often occurs simultaneously with depression, and
mixed anxiety-depression is found to be present in 90% of
depressed patients after AMI [9]. After percutaneous coro-
nary intervention (PCI) patients, who had symptoms of
both anxiety and depression, reported poorer health sta-
tus compared to patients, who only had anxiety or depres-
sion or no symptoms [10]. Furthermore, post-AMI anxiety
is an independent predictor for both cardiac events and
rehospitalizations [11,12]. A history of depression is asso-
ciated with more frequent angina and poor quality of life
after ACS [13]. Depression is related to severity of cardiac
disease, depressive symptoms are more frequent in
patients with left ventricle dysfunction [14] and have neg-
ative influence on the cardiovascular prognosis [6]. Only
few randomized trials examined whether treating depres-
sion in cardiac patients could improve prognosis.
ENRICHD (Enhancing Recovery in Coronary Heart Dis-
ease) included 2,481 post-AMI patients with major
depression and (or) low social support. The study showed
no effect of cognitive behavioural therapy on cardiac
prognosis [15]. SADHART (Sertraline Antidepressant
Heart Attack Randomized Trial) used the selective serot-
onin reuptake inhibitor (SSRI) sertraline for treatment of
post-ACS depression. A reduction in depressive symptoms
in patients treated with sertraline was found, but overall
the impact on the score of Hamilton Depression Scale
(HDS) was not significant [16]. In MIND-IT (Myocardial
Infarction and Depression – Intervention Trial) study 331
depressed AMI patients were enrolled in double blind,
placebo-controlled study with mirtazapine. No differ-
ences in depression status were found in patients in the
mirtazapine arm of the study and the care-as-usual arm at
18 months post-AMI [17]. In Canada the CREATE (Car-
diac Randomized Evaluation of Antidepressant and Psy-
chotherapy Efficacy) study was conducted among 284
outpatients with coronary artery disease (CAD) and
depression. The SSRI citalopram was found to be superior
to placebo in reducing HDS scores, but no benefit of inter-
personal psychotherapy was evident [18]. In a recent sys-
tematic review Thombs et al [19] identified 6 depression
treatment trials in patients with cardiovascular disease.
The treatment of depression was associated with modest
improvement in depressive symptoms but no improve-
ment in cardiac outcomes.
Several biological links have been proposed to explain the
relationship between cardiac disease and depression.
Heart rate variability (HRV) reflects the sympathetic/para-
sympathetic balance in the autonomic regulation of the
heart, as well as the capacity of the autonomic nervous
system to vary the intervals between consecutive heart-
beats. HRV may be reduced in depressed patients with
CAD [20-24], and it has been proposed, that treating
depression in CAD patients with cognitive behavioural
therapy may increase HRV [22]. Treatment with SSRIs
appears to normalize low HRV in depressive patients
without any heart disease [25], but it is still unknown
whether it influences mortality.
Platelets play a crucial role in the development of athero-
sclerosis and ACS, and several studies have shown
increased platelet activity in depressed patients with
ischemic heart disease [26,27]. SSRIs influence platelet
activity by blocking reuptake of serotonin and thereby
reducing the activity of platelets. It has been demonstrated
that SSRIs may even reduce platelet activity in cardiac
patients without depression [28,29].
Vascular endothelial dysfunction also plays an important
role in the relation between depression and heart disease.
Arterial endothelial function measured by flow-mediated
dilation is impaired in patients treated for depression
[30,31] as well as in patients with documented coronary
heart disease and depressive symptoms. Treatment with
antidepressants seems to be associated with improved
flow-mediated dilation [31].
The diagnosis of depression in post-ACS patients presents
several problems in itself. In a significant number of these
patients symptoms of depression are poorly recognized
[32]. On the other hand, cardiac patients may be wrongly
diagnosed as depressed due to diagnostic overlap of
somatic symptoms such as fatigue and insomnia [1]. It is
still unknown whether screening for depression is of ben-
efit in patients with cardiovascular disease [19].
Based on the above mentioned studies we planned to test
the hypothesis if 1-year treatment with a SSRI drug (escit-
alopram), which has beneficial cardiovascular effects, can
prevent depression in post-ACS patients, and to examine
the influence of the drug in cardiovascular variables
known to be related to cardiovascular prognosis.
Methods
Overview
The DEpression in Coronary ARtery Disease (DECARD)
study is an investigator-initiated and driven study and 240
non-depressed patients with ACS are enrolled. The
patients enter a 1-year treatment, randomly assigned to
either escitalopram or placebo.
Eligibility criteria
Inclusion criteria
1. Admission to the coronary care unit for ACS [33];
2. Randomization within 8 weeks from index hospitaliza-
tion for ACS;
3. Age > 18 years;Page 2 of 9
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study if they have a negative pregnancy test and use an
effective mean of contraception;
5. Signed informed consent.
Exclusion criteria
1. Current depression based on Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) [34] diagnos-
tic criteria of depression and/or a score of 13 or more
on the 17-item HDS;
2. Use of antidepressants or antipsychotic medication
within 4 weeks preceding enrolment;
3. Previous intolerance to SSRI;
4. Severe, life-threatening medical conditions imply-
ing, that the patient cannot participate in the 1-year
study course;
5. Severe congestive heart failure defined as New York
Heart Association (NYHA) functional class IV;
6. Current alcohol or substance abuse;
7. Psychosis or dementia;
8. Current participation in other intervention trials;
9. Pregnancy and lactation;
10. Linguistic difficulties or not mastering Danish.
Recruiting Process
All patients admitted to two departments of cardiology at
Bispebjerg and Amager University Hospitals, Copenhagen
are screened for ACS. The diagnosis of ACS is made by the
doctor in charge at the coronary care units. Patients, who
meet the inclusion criteria and none of the exclusion cri-
teria, are asked to participate in the study by a study doc-
tor or nurse. Patients are recruited during their stay at the
hospital or contacted after discharge within eight weeks
from hospitalization.
In order to compare participants and non-participants,
four questions from the Primary Care Evaluation of Men-
tal Disorders (PRIME-MD) [35] screening questionnaire
concerning mood and anxiety are administrated to all eli-
gible patients. Patients are not in- or excluded on basis of
the PRIME-MD screening.
The potentially eligible patients are examined using SCAN
interview. SCAN interview is applied by one of the three
investigators in the study. (see Figure 1)
Ethics and informed consent
The study is conducted in accordance with the Helsinki
Declaration and is approved by The Danish National
Committee on Biomedical Research Ethics, Identifier:
(KF) 02-025/03, The Danish Medicines Agency, Identifier:
2612–2274, and The Danish Data Protection Agency,
Identifier: 2004-54-1621.
All eligible patients receive written information and are
simultaneously informed about the study by a study
nurse. Before entering the study patients are informed
about study objectives, study design and potential risks
and benefits by one of the main investigators. Patients are
also informed about their right to withdraw from the
study at any time. Written consent is obtained from each
patient. After informed consent the general practitioners
are informed by mail about the patients entering in the
study.
The DECARD trial is monitored by the Institute of Good
Clinical Practice of University of Copenhagen.
Randomization and blinding
After signing of the informed consent form, baseline data
are collected and patients consecutively randomized to a
double-blind treatment with either escitalopram or pla-
cebo. Patients are randomized in centrally prepared rand-
omization blocs. The randomization is done
independently of the researchers. The allocation sequence
is implemented using the consecutive number of the
study medication. Patients undergoing coronary artery
bypass graft (CABG) surgery are stratified to a separate
randomized group due to expected difference in outcome
after major surgery versus PCI or non-invasive treatment.
Investigators, nurses, outcome assessors as well as patients
remain blinded to group assignment during the entire
intervention and data analysis.
Psychiatric assessment
After demographic data collection during the baseline
visit, SCAN is administrated using selected chapters
regarding depression and anxiety (Part I, Chapters 3, 4, 6,
7, 8 and 21). This semi-structured diagnostic interview is
used to exclude depression in patients entering the study.
All investigators have completed the WHO certified train-
ing course in SCAN. Information on current and previous
mental illnesses as well as the family history of mental ill-
nesses is also obtained.
During all visits patients are assessed using the 17-items
HDS [36], Hamilton Anxiety Scale (HAS) [37] and Clini-
cal Global Impression (CGI) [38]. Tolerability of study
treatment and possible side effects are registered by using
the UKU Side Effect Rating Scale [39]. Inter-rater reliabil-
ity is assured by regular HDS and HAS training sessions.Page 3 of 9
(page number not for citation purposes)
Trials 2009, 10:20 http://www.trialsjournal.com/content/10/1/20
Page 4 of 9
(page number not for citation purposes)
flow chartFigure 1
flow chart.
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Trials 2009, 10:20 http://www.trialsjournal.com/content/10/1/20Furthermore, several self-administrated questionnaires
are used for assessment of psychopathology. Beck Depres-
sion Inventory (BDI) [40] is administrated following the
interview at every visit. At baseline and during fifth and
ninth visit (i.e. weeks 0, 26 and 52) general psychopathol-
ogy is assessed with the Symptom Checklist (SCL-92)
[41], while function and social support is evaluated with
the SF-36 Health Survey (SF-36) [42] and ENRICHD
Social Support Instrument (ESSI) [43].
Cardiac assessment
Cardiac evaluation is performed at baseline, weeks 26 and
52 at the end of treatment and includes information of
risk factors for cardiovascular disease (smoking, diabetes,
history of arterial hypertension, family history of CAD,
physical activity), alcohol consumption, and current med-
ications.
Canadian Cardiovascular Society (CCS) Classification for
angina and NYHA functional class are estimated and arte-
rial blood pressure measured.
A 24-hour Holter ECG monitoring is done at baseline and
at weeks 26 and 52. All recordings are analysed at the ECG
core laboratory at Hvidovre University Hospital to meas-
ure HRV and detect possible arrhythmias and silent myo-
cardial ischemia.
A standard echocardiographic examination assessing left
ventricular function is carried out at baseline and at weeks
26 and 52.
A 12-lead ECG is obtained to be analysed for atrioven-
tricular and intraventricular conduction as well as QTc
interval as cardiac safety measure.
Biochemical analysis includes full blood cell count, com-
plete blood chemistry, fasting lipid profile, brain natriu-
retic peptide (pro-BNP), and High sensitivity-C-reactive
protein (HS-CRP).
Patients, who due to depression or any other reason ter-
minate before 52 weeks, are asked to complete final
assessment equal to last visit in the study.
Study medication
Study medication escitalopram (Cipralex) is provided by
H. Lundbeck A/S, Denmark. Escitalopram is a highly
selective SSRI with a fairly rapid onset of antidepressant
activity. Escitalopram was chosen because its favourable
side-effect profile and being a weak inhibitor of CYP2D6
it has a very low potential for drug-drug interactions [44].
The medication is packed by Pharmacy "Region Hoveds-
tadens Apotek" and is delivered in identical blister packs
for placebo and escitalopram. Medication is administered
once daily. Code-break cards are stored in the Trial Master
File in case the randomization code of the medication has
to be broken before the end of the trial.
Patients receive an initial dose of 5 mg escitalopram or
matching placebo (week 1) with dose increase to 10 mg
(week 2). Although the dose of escitalopram used for
treatment of depression is 20 mg we decided to use 10 mg
as it is the recommended dose for people older than 65
years and a substantial part of study participants are older
than 65 years. Pill count is performed at each visit.
Compliance is defined as taking at least 75% of study
medication. In order to avoid disruption syndrome
patients receive half dosage (5 mg escitalopram or pla-
cebo) for 14 days before the study medication is with-
drawn.
Intervention
Patients are seen at 9 visits during the year of study partic-
ipation. Visits are spaced with two weeks between the first
and second visit, 6 weeks between the second and the
third visit and approximately 7 weeks between visits dur-
ing the remaining study period. It is rendered important
to see patients two weeks after initiation of treatment, in
order to handle possible side effects of the study medica-
tion, insure compliance, and answer possible questions.
If patients during the study period develop HDS score 13
or more [45], the investigator increases the dose of escita-
lopram/placebo to 20 mg and patients are seen at an
extraordinary visit approximately 14 days later, where the
ICD-10 criteria for depressive episode are applied by a
psychiatrist. Patients diagnosed as having a moderate or
severe depressive episode, terminate the study medication
and are offered an open treatment for depression.
Symptoms of anxiety are assessed at each visit using HAS,
but the intervention is not changed or terminated in case
of worsened symptoms of anxiety.
Measurements of serotonin level in a subpopulation
In order to investigate the influence of long-term treat-
ment with SSRI on serotonin level, a substudy is per-
formed on 60 patients measuring the level of serotonin in
platelets. A blood sample is drawn at baseline, after 26
weeks, 52 weeks as well as 4 weeks after discontinuation
of study medication. This substudy is done in cooperation
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Secondary (safety) endpoints
1. changes in 24-hour and 15-minute day and night HRV
(time- and frequency domains) over time and episodes
ventricular arrhythmias registered by 24-hour ambulatory
ECG;
2. changes in pro-BNP and HS-CRP over time;
3. incidence of cardiovascular events defined as recurrent
ACS and unplanned revascularisation;
4. changes in self-rated physical health and quality of life
(SF-36);
5. changes in anxiety level measured by HAS and SCL-92
anxiety scale;
6. utilization of health services during the study period;
Sample size, data analysis and statistical methods
Sample size is calculated on the basis of the assumption,
that 30% of patients the first year after ACS will develop a
moderate or severe depressive episode [46] which can be
reduced to 15% by SSRI treatment. Power calculation is
based on a two-sided test, and with a power of 0.80 and
the significance level α = 0.05, the required sample size in
each group is 117. There are no interim efficacy analyses
planned.
Data are entered in excel and then in SPSS. Data quality is
assured by double-entering of 10% of all data. Data are
analysed according to both intention-to-treat and per-pro-
tocol (efficacy population) principle using SPSS version
15 (SPSS Inc., Chicago, IL). Intention-to-treat population
is defined as all randomized patients. Per-protocol analy-
ses include patients taking study medication for more
than 14 days and having no violation of eligibility criteria.
The statistical analyses are performed blinded, i.e. ana-
lysed without breaking the code, and with the patients
belonging to either group A or B.
The null hypothesis is that no difference will be demon-
strated in the number of patients developing a moderate
or severe depressive episode during the study period
between the escitalopram and placebo groups. The cumu-
lative incidences of outcomes (depressive episodes) as
well as secondary outcomes (incidence of arrhythmias
and cardiovascular events) by treatment group are exam-
ined by Kaplan-Meier plots. Subsequently, the relation-
ship between the two treatments and depressive episodes
is examined using the Cox proportional-hazards model
with the study period as the underlying time. In subse-
quent models the relationship is adjusted for age, gender,
social class, physical activity, psychiatric comorbidity and
cardiac risk factors at baseline. A forward selection and a
backward selection are conducted, excluding the non-sig-
nificant variables for each model. Continuous variables
are tested for linearity and if linearity is not present, the
variables will be included as discrete variables in the mod-
els. The two treatment groups at baseline are compared
using 2-way ANOVA for continuous measures and Chi-
square tests for nominal data. Further analyses are two-
factor mixed design, repeated measure with outcome var-
iables after treatment as dependent variables and outcome
variables before treatment as covariates. Missing data are
imputed as last observation carried forward. The two treat-
ment groups are between-subject factors and time 0, 6 and
12 months after treatment are within-subject factors. For
each analysis a 95% confidence interval is derived. All
tests of statistical significance are interpreted with a crite-
rion of p < 0.05.
Discussion
This paper reports the protocol of the first study recruiting
non-depressed post-ACS patients for preventive treatment
of depression with escitalopram or placebo. A negative
impact of depression and anxiety on outcome of ACS is
well-established, but depression and anxiety in ACS
patients often remain unrecognized and untreated [2,9].
Most clinical trials concerning mental disorders in ACS
have targeted the treatment of an already established
depressive state. In contrast, we have designed a study of
prevention in ACS patients definitely not having depres-
sion at baseline.
As depression worsen the prognosis of cardiac patients it
might be possible to improve prognosis by prevention of
depression using antidepressive medication. SSRIs can
prevent recurrent depression [47] and depressive episodes
in patients with diabetes [48].
Tricyclic antidepressants (TCAs) have been used with cau-
tion in ACS patients due to risk of serious adverse cardiac
events. In contrast, SSRIs are a safe and effective medica-
tion in the cardiac population [16,49]. In a randomized
study of the prevention of depression in stroke patients
SSRI (sertraline) was safe and compared to placebo dem-
onstrated a reduction in cardiovascular events [50].
Escitalopram is a SSRI developed to the treatment of
patients with depression [44]. No long-term treatment
studies with escitalopram in cardiac patients have yet
been published, but a study with escitalopram assessing
safety and tolerability of the drug in long-term treatment,
i.e. 12 months in depressed patients, demonstrated that
escitalopram is well-tolerated. The overall withdrawal rate
was 26% and the withdrawal rate due to adverse events
was 9%, which is lower than seen with most other antide-Page 6 of 9
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event profile [51].
The selection of SSRI in this trial is based on previous
studies supporting their safety in patients with cardiovas-
cular disease without any association with cardiovascular
adverse events [52]. SSRIs block the reuptake of serotonin
including in platelets, which contain but do not synthe-
size serotonin. Treatment with SSRIs leads to depletion of
serotonin in platelets [53,54], this in turn results in lower
activity of platelets [55] and reduced aggregation [56].
This supports the hypothesis that SSRIs may reduce the
risk of myocardial infarction [57-59] as lower platelet
serotonin content may lead to less serotonin release dur-
ing platelet activation at an intra-coronary stenosis [60].
Bleeding might be a side effect of SSRI treatment, but stud-
ies have shown conflicting results.
Though several studies have suggested that SSRIs may
increase the risk of bleeding [59,61-63], especially in
patients also taking non-steroidal anti-inflammatory
drugs (NSAIDs) [64], one study did not find an increased
bleeding risk when NSAIDs and SSRIs were prescribed
together, compared to taking the each drug separately
[65]. Furthermore, treating depressed CAD patients with
citalopram reduced HDS scores and showed no differ-
ences between citalopram and placebo in bleeding ten-
dencies [18].
The cardioprotective properties of the SSRI's may also be
explained by the SSRI's effect on heart rhythm. The SSRI
sertraline in post AMI depressed patients facilitated the
recovery of HRV, which is an expression of cardiac auto-
nomic function [66].
Changes in cardiovascular risk factors may influence the
long-term prognosis in post-ACS patients. By repeated
registration of risk factors, HRV, and biochemical mark-
ers, i.e. serum lipids, CRP and pro-BNP, it is possible to
describe differences and changes over time in cardiovascu-
lar risk in the two treatment groups and to evaluate inter-
action between risk factors and trial medication.
Several studies have examined other psychosocial risk fac-
tors than depression and several of these factors are
included in the present study. Anxiety has been shown to
be a cardiac risk factor [11], and is measured by a well
known interview based instrument (HAS), as well as by
self-rating (SCL-92). Social support and quality of life are
measured with ESSI and SF-36, both instruments previ-
ously performing satisfactorily in studies on cardiac risk
factors [43,67].
The clinical study was initiated at the end of 2004.
Patients in this study are treated in two coronary care units
in accordance with recent guidelines [68]. All patients
with UAP and with post AMI signs of myocardial ischemia
are referred for coronary angiography, and if indicated
PCI or CABG. Post PCI patients with stent implantation
are treated with clopidogrel for 12 months. Standard sec-
ondary prevention with beta-blockers, calcium channel
antagonists, statins, ACE/angiotensin-II antagonists, and
aspirin are used in accordance with the guidelines. All
medication during the study period is monitored. The
inclusion of patients was estimated to take 18 months but
due to slower-than-expected enrolment was extended
until the end of 2007. During the study period no signifi-
cant changes in the guidelines for treatment of patients
with ACS took place.
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